Skip to main content
OpenTrials
Completed

NCT Number: NCT02859246

Mucinex® for Treatment of Filamentary Keratitis

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Filamentary Keratitis

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, 02114, United States

About this study

The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with filamentary keratitis
  • 18 years and older

Exclusion criteria

  • Active ocular surface infection of any type
  • Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
  • Schirmer's test<3mm
  • History of hypersensitivity to Mucinex®
  • Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Treatment and study plan

Mucinex®

Drug

Mucinex®

Other names: Guaifenesin

Primary outcomes

  1. Change in Number of Corneal Filaments

    Time frame: baseline (day 1) and week 4

    Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.

Secondary outcomes

  1. Change in OSDI Score

    Time frame: baseline (day 1) and week 4

    Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.

    Total score ranges from 0-100. Lower OSDI scores means subjects are experiencing low ocular discomfort. High OSDI scores means subjects are experiencing high ocular discomfort.

Sponsors and collaborators

Lead sponsor

Massachusetts Eye and Ear Infirmary

Other

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Aug 9, 2016
Registry last updated
Feb 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.